medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2019, Number 1

<< Back Next >>

Acta Ortop Mex 2019; 33 (1)

Atypical femoral fracture, case report and literature review

Cleto-Zepeda G, Durán-Martínez N, Tena-Sanabria ME

Language: English
References: 12
Page: 39-41
PDF size: 206.85 Kb.


ABSTRACT

Introduction: Bisphosphonates have been the gold standard in the management of osteoporosis. Its antiresorptive effect has reduced the incidence of fractures due to bone fragility, as well as its impact on public health. We present the clinical case of a patient in prolonged treatment with bisphosphonates and atypical bilateral femur fracture. Case report:A 65-year-old female who presented a fall from her own height, on treatment with risedronate for seven years, and a history of systemic arterial hypertension and hypercholesterolemia, both with medical treatment. Diagnosed with bilateral atypical femoral fracture, treated with closed reduction internal fixation (CRIF) with intramedullary nailing, application of calcium citrate and teriparatide. Discussion: Multiple studies indicate that the benefit of using bisphosphonates for osteoporosis is higher than the risk of presenting atypical fractures.


REFERENCES

  1. Iqbal MM. Osteoporosis: epidemiology, diagnosis, and treatment. South Med J. 2000; 93(1): 2-18.

  2. Im GI, Jeong SH. Pathogenesis, management and prevention of atypical femoral fractures. J Bone Metab. 2015; 22(1): 1-8.

  3. Edwards BJ, Bunta AD, Lane J, Odvina C, Rao DS, Raisch DW, et al. Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am. 2013; 95(4): 297-307.

  4. Bubbear JS. Atypical femur fractures in patients treated with bisphosphonates: identification, management, and prevention. Rambam Maimonides Med J. 2016; 7(4). doi: 10.5041/RMMJ.10259.

  5. Geissler JR, Bajaj D, Fritton JC. American Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures. J Biomech. 2015; 48(6): 883-94.

  6. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014; 29(1): 1-23.

  7. Takemoto RC, McLaurin TM, Tejwani N, Egol KA. Evolution of atypical femur fractures and the association with bisphosphonates. Bull Hosp Jt Dis (2013). 2014; 72(1): 104-9.

  8. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90(3): 1294-301.

  9. Saita Y, Ishijima M, Kaneko K. Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications. Ther Adv Chronic Dis. 2015; 6(4): 185-93.

  10. Caeiro-Rey JR, Etxebarria-Foronda I, Mesa-Ramos M. Fracturas atípicas relacionadas con el uso prolongado de bifosfonatos. Estado de la situación. Rev Esp Cir Ortop Traumatol. 2011; 55(5): 392-404.

  11. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016; 31(1): 16-35.

  12. Im GI, Lee SH. Effect of teriparatide on healing of atypical femoral fractures: a systemic review. J Bone Metab. 2015; 22(4): 183-9.




2020     |     www.medigraphic.com